Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among US Men Who Have Sex with Men

被引:103
作者
Greene, George J. [1 ,2 ]
Swann, Greg [1 ,2 ]
Fought, Angela J. [3 ]
Carballo-Dieguez, Alex [4 ,5 ]
Hope, Thomas J. [6 ]
Kiser, Patrick F. [7 ]
Mustanski, Brian [1 ,2 ]
D'Aquila, Richard T. [8 ,9 ]
机构
[1] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Inst Sexual & Gender Minor Hlth & Wellbeing, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA
[4] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[5] Columbia Univ, Med Ctr, New York, NY USA
[6] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA
[7] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA
[8] Northwestern Univ, Feinberg Sch Med, Dept Med Infect Dis, HIV Translat Res Ctr, Arthur J Rubloff Bldg,750 N Lake Shore Dr, Chicago, IL 60611 USA
[9] Northwestern Univ, Feinberg Sch Med, Coast Ctr AIDS Res 3, Arthur J Rubloff Bldg,750 N Lake Shore Dr, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
HIV; Homosexuality; Male; Pre-exposure prophylaxis; Prevention; Sexual behavior; GAY PRIDE EVENTS; ANTIRETROVIRAL PROPHYLAXIS; HIGH-RISK; POSTEXPOSURE PROPHYLAXIS; LIMITED KNOWLEDGE; YOUNG MEN; INFECTION; ATTENDEES; TENOFOVIR; ADHERENCE;
D O I
10.1007/s10461-016-1565-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
HIV prevention method preferences were evaluated among 512 U.S. men who have sex with men (MSM; median age: 22 years). Approximately 90 % consistently preferred one option across pairwise comparisons of condoms, daily oral pre-exposure prophylaxis (PrEP), and long-acting PrEP delivered via either an injectable or one of two types of PrEP implants differing in visibility. Condoms were most frequently preferred (33.8 %), followed by non-visible implants (21.5 %), and oral PrEP (17.0 %); HIV risk was reported by more choosing implants. In a follow-up question comparing the four PrEP options only, daily oral pills and non-visible implants were most frequently preferred (35.5 and 34.3 %, respectively), followed by injections (25.2 %) and visible implants (4.3 %). An inductive, open-coding approach determined that convenience, duration of protection, and privacy were the most commonly cited reasons for a PrEP method choice, and associated with self-report of HIV risk. Tailoring PrEP product development to privacy and other concerns important to those at highest HIV risk may improve HIV prevention.
引用
收藏
页码:1336 / 1349
页数:14
相关论文
共 61 条
[1]   Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey [J].
Aghaizu, Adamma ;
Mercey, Danielle ;
Copas, Andrew ;
Johnson, Anne M. ;
Hart, Graham ;
Nardone, Anthony .
SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 (03) :207-211
[2]   Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment [J].
Amico, K. R. ;
McMahan, Vanessa ;
Goicochea, Pedro ;
Vargas, Lorena ;
Marcus, Julia L. ;
Grant, Robert M. ;
Liu, Albert .
AIDS AND BEHAVIOR, 2012, 16 (05) :1243-1259
[3]   Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence [J].
Amico, K. Rivet ;
Stirratt, Michael J. .
CLINICAL INFECTIOUS DISEASES, 2014, 59 :S55-S60
[4]   Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men [J].
Anderson, Peter L. ;
Glidden, David V. ;
Liu, Albert ;
Buchbinder, Susan ;
Lama, Javier R. ;
Vicente Guanira, Juan ;
McMahan, Vanessa ;
Bushman, Lane R. ;
Casapia, Martin ;
Montoya-Herrera, Orlando ;
Veloso, Valdilea G. ;
Mayer, Kenneth H. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Kallas, Esper Georges ;
Grant, Robert M. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (151)
[5]  
[Anonymous], 2015, HIV GAY BIS MEN
[6]  
[Anonymous], 2015, HIV SURV REP
[7]  
[Anonymous], HIV SURV MEN WHO HAV
[8]  
[Anonymous], C RETR OPP INF CROI
[9]  
[Anonymous], C RETR OPP INF CROI
[10]   Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women [J].
Baeten, J. M. ;
Palanee-Phillips, T. ;
Brown, E. R. ;
Schwartz, K. ;
Soto-Torres, L. E. ;
Govender, V. ;
Mgodi, N. M. ;
Kiweewa, F. Matovu ;
Nair, G. ;
Mhlanga, F. ;
Siva, S. ;
Bekker, L. -G. ;
Jeenarain, N. ;
Gaffoor, Z. ;
Martinson, F. ;
Makanani, B. ;
Pather, A. ;
Naidoo, L. ;
Husnik, M. ;
Richardson, B. A. ;
Parikh, U. M. ;
Mellors, J. W. ;
Marzinke, M. A. ;
Hendrix, C. W. ;
van der Straten, A. ;
Ramjee, G. ;
Chirenje, Z. M. ;
Nakabiito, C. ;
Taha, T. E. ;
Jones, J. ;
Mayo, A. ;
Scheckter, R. ;
Berthiaume, J. ;
Livant, E. ;
Jacobson, C. ;
Ndase, P. ;
White, R. ;
Patterson, K. ;
Germuga, D. ;
Galaska, B. ;
Bunge, K. ;
Singh, D. ;
Szydlo, D. W. ;
Montgomery, E. T. ;
Mensch, B. S. ;
Torjesen, K. ;
Grossman, C. I. ;
Chakhtoura, N. ;
Nel, A. ;
Rosenberg, Z. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) :2121-2132